Breaking News
January 19, 2019 - New Leash on Life? Staying Slim Keeps Pooches Happy, Healthy
January 19, 2019 - Men and women remember pain differently
January 19, 2019 - Rising air pollution linked with increased ER visits for breathing problems
January 19, 2019 - Study uses local data to model food consumption patterns among Seattle residents
January 19, 2019 - The brain’s cerebellum plays role in controlling reward and social behaviors, study shows
January 19, 2019 - Relationship between nurse work environment and patient safety
January 19, 2019 - Pioneering surgery restores movement to children paralyzed by acute flaccid myelitis
January 19, 2019 - Genetic variants linked with risk tolerance and risky behaviors
January 19, 2019 - New research provides better understanding of our early human ancestors
January 19, 2019 - First-ever tailored reporting guidance to improve patient care and outcomes
January 19, 2019 - 4.6 percent of Massachusetts residents have opioid use disorder
January 19, 2019 - New study suggests vital exhaustion as risk factor for dementia
January 19, 2019 - New antibiotic discovery heralds breakthrough in the fight against drug-resistant bacteria
January 19, 2019 - Ural Federal University scientists synthesize a group of multi-purpose fluorophores
January 19, 2019 - Researchers identify new therapeutic target in the fight against chronic liver diseases
January 19, 2019 - Preparation, characterization of Soyasapogenol B loaded onto functionalized MWCNTs
January 19, 2019 - FDA Approves Ontruzant (trastuzumab-dttb), a Biosimilar to Herceptin
January 19, 2019 - Tobacco use linked with higher use of opioids and sedatives
January 19, 2019 - Study delves deeper into developmental dyslexia
January 19, 2019 - Anti-vaccination movement one of the top health threats in 2019 says WHO
January 19, 2019 - Newly developed risk score more effective at identifying type 1 diabetes
January 19, 2019 - Highly effective protocol to prepare cannabis samples for THC/CBD analysis
January 19, 2019 - Prinston Pharmaceutical Inc. Issues Voluntary Nationwide Recall of Irbesartan and Irbesartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodiethylamine (NDEA) in the Products
January 19, 2019 - How does solid stress from brain tumors cause neuronal loss, neurologic dysfunction?
January 19, 2019 - $14.7 million partnership to supercharge vaccine development
January 19, 2019 - Ian Fotheringham receives Charles Tennant Memorial Lecture award
January 19, 2019 - Brain vital signs detect neurophysiological impairments in players with concussions
January 19, 2019 - Lack of job and poor housing conditions increased likelihood of people attending A&E
January 19, 2019 - Novel targeted drug delivery system improves conventional cancer treatments
January 19, 2019 - Rutgers study finds gene responsible for spread of prostate cancer
January 19, 2019 - Complications Higher Than Expected for Invasive Lung Tests
January 19, 2019 - 3-D printed implant promotes nerve cell growth to treat spinal cord injury
January 19, 2019 - Automated texts lead to improved outcomes after total knee or hip replacement surgery
January 19, 2019 - Poor cardiorespiratory fitness could increase risk of future heart attack, finds new study
January 19, 2019 - Drinking soft drinks while exercising in hot weather may increase risk of kidney disease
January 19, 2019 - Formlabs 3D prints anatomical models
January 19, 2019 - Heart-Healthy Living Also Wards Off Type 2 Diabetes
January 19, 2019 - Teaching Kids to Be Smart About Social Media (for Parents)
January 19, 2019 - Metabolite produced by gut microbiota from pomegranates reduces inflammatory bowel disease
January 19, 2019 - Researchers examine how spray from showers and toilets expose us to disease causing bacteria
January 19, 2019 - Behavioral experiments confirm that additional neurons improve brain function
January 19, 2019 - New study compares performance of real-time infectious disease forecasting models
January 19, 2019 - Obesity can be risk factor for developing renal cell carcinoma, confirms study
January 19, 2019 - New regulation designs on cigarette packs direct smokers’ attention to health warnings
January 19, 2019 - QIAGEN receives first companion diagnostic approval in Japan
January 19, 2019 - Study explores role of Dunning-Kruger effect in anti-vaccine attitudes
January 19, 2019 - Newly identified subset of immune cells may be key to fighting chronic inflammation
January 19, 2019 - New immune response regulators discovered
January 18, 2019 - Poor blood oxygenation during sleep predicts chance of heart-related death
January 18, 2019 - First international consensus on the diagnosis and management of fibromuscular dysplasia
January 18, 2019 - Rapid resistance gene sequencing technology can hasten identification of antibiotic-resistant bacteria
January 18, 2019 - Researchers develop artificial enzymatic pathway for synthesizing isoprenoids in E. coli
January 18, 2019 - Scientists advise caution in immunotherapy research
January 18, 2019 - How children across the world develop language
January 18, 2019 - Columbia Medical Student Receives McDonogh Scholarship
January 18, 2019 - Secretive ‘Rebate Trap’ Keeps Generic Drugs For Diabetes And Other Ills Out Of Reach
January 18, 2019 - Plant based diet could be the best option for the planet says commission
January 18, 2019 - New conservation practice could reduce nitrogen from agricultural drainage, study shows
January 18, 2019 - UIC researchers receive $1.7 million NCI grant to study Southeast Asian fruit
January 18, 2019 - New study determines the fate of DNA derived from genetically modified food
January 18, 2019 - Scientists develop new gene therapy that prevents axon destruction in mice
January 18, 2019 - Study finds critically low HPV vaccination rates among younger adolescents in the U.S.
January 18, 2019 - Brain cells involved in memory play key role in reducing future eating behavior
January 18, 2019 - Risk for Conversion of MS Varies With Different Therapies
January 18, 2019 - Investigational cream may help patients with inflammatory skin disease
January 18, 2019 - Medical school news office receives six writing awards | News Center
January 18, 2019 - County By County, Researchers Link Opioid Deaths To Drugmakers’ Marketing
January 18, 2019 - Research reveals risk for developing more than one mental health disorder
January 18, 2019 - Scientists discover a dramatic pattern of bone growth in female mice
January 18, 2019 - Study finds link between lengthy periods of undisturbed maternal sleep and stillbirths
January 18, 2019 - New nuclear medicine method could improve detection of primary and metastatic melanoma
January 18, 2019 - Combination therapy shows high efficacy in treating people with leishmaniasis and HIV
January 18, 2019 - Health Tip: Don’t Ignore Changes in Skin Color
January 18, 2019 - Dietary Recommendations for Healthy Children
January 18, 2019 - Eliminating the latent reservoir of HIV
January 18, 2019 - Pain From The Government Shutdown Spreads. This Time It’s Food Stamps
January 18, 2019 - Newly discovered regulatory mechanism helps control fat metabolism
January 18, 2019 - New rapid blood tests could speed up TB diagnosis, save the NHS money
January 18, 2019 - Researchers develop intelligent system for ‘tuning’ powered prosthetic knees
January 18, 2019 - Monoclonal antibody pembrolizumab prolongs survival in patients with squamous cell carcinoma
Death Rate Falls with Anti-TNF in Crohn’s

Death Rate Falls with Anti-TNF in Crohn’s

image_pdfDownload PDFimage_print

Action Points

  • Patients with Crohn’s disease (CD) treated with tumor necrosis factor (TNF) inhibitors had a statistically significant reduction in mortality relative to those treated with prolonged corticosteroid therapy, in a large retrospective study.
  • Note that the association of anti-TNF therapy and reduced mortality was in the same direction but not statistically significant among patients with ulcerative colitis (UC).

Patients with Crohn’s disease who were treated with tumor necrosis factor (TNF) inhibitors had a lower mortality risk than those who had prolonged corticosteroid therapy, a large retrospective cohort study found.

Among 1,879 Crohn’s patients initiating anti-TNF therapy, there was a significantly lower risk of death (OR 0.78, 95% CI 0.65-0.93) compared with risks for 7,694 patients treated with long-term steroids, according to James D. Lewis, MD, director of the Gastroenterology and Hepatology Clinical Research Program at the University of Pennsylvania in Philadelphia, and colleagues.

And while the mortality risk was numerically lower for patients with ulcerative colitis receiving anti-TNF treatment (n=459), the difference compared with steroid users (n=3,224) was not statistically significant (OR 0.87, 95% CI 0.63-1.22), the researchers reported in the American Journal of Gastroenterology.

“The reduced mortality rates among patients with Crohn’s disease was potentially a consequence of excess cardiovascular-related mortality and hip fractures and was largely limited to patients with multiple or serious comorbid conditions.”

Corticosteroids and anti-TNF therapies both are widely used in the treatment of inflammatory bowel disease, but both approaches are associated with potentially serious — and even fatal — adverse events, the team explained. Both classes of drugs are associated with serious infections and congestive heart failure, anti-TNFs have been linked with cancer, and corticosteroids are associated with pulmonary embolism and osteoporosis/fractures. Moreover, uncontrolled disease may itself raise the mortality risk.

Previous studies have demonstrated an increased mortality risk among patients with inflammatory bowel disease treated with corticosteroids, but studies assessing anti-TNF therapy have not had clear-cut results. Previous work also has not considered potentially important factors such as comorbid illness and older age in evaluating risk of death.

Lewis and colleagues therefore analyzed outcomes among patients with inflammatory bowel disease enrolled in Medicare from 2006 to 2013 and in Medicaid from 2001 to 2005.

The anti-TNF group included those who had at least one prescription for infliximab (Remicade), adalimumab (Humira), or certolizumab pegol (Cimzia) during the previous year, while the prolonged corticosteroid group included those with at least 3,000 mg prednisone or 600 mg of budesonide exposure within the past 12 months.

The primary outcome was all-cause mortality, and secondary endpoints included major adverse cardiovascular events, cancer, hip fracture, pulmonary embolism, serious infection, and emergency bowel resection. The analysis was conducted using marginal structural models and propensity scoring.

Total follow-up times among the Crohn’s disease patients were 6,222 person-years in the anti-TNF group and 24,625 person-years in the prolonged steroid group, while the corresponding numbers for ulcerative colitis were 1,213 and 9,158 person-years, respectively.

During follow-up, 1,444 patients died, with mean ages at death of 67 for patients with Crohn’s disease and 76.7 for those with ulcerative colitis.

The weighted annual incidence of death among patients with Crohn’s disease was 21.4 per 1,000 patients in the anti-TNF group and 30.1 per 1,000 in the prolonged steroid group. For ulcerative colitis, the corresponding numbers were 23 and 30.9 per 1,000, respectively.

The association between anti-TNF use and mortality risk did not differ according to age, but the lower mortality was seen only among patients with comorbidity scores higher than 3, with odds ratios of 0.65 (95% CI 0.48-0.88) for Crohn’s disease and 0.63 (95% CI 0.36-1.11) for ulcerative colitis.

For secondary endpoints among Crohn’s disease patients, anti-TNF therapy was associated with decreased risks of major adverse cardiovascular events (OR 0.68, 95% CI 0.55-0.85) and hip fracture (OR 0.54, 95% CI 0.34-0.83), although these decreased risks were not seen in patients with ulcerative colitis.

The observation that the risk of major adverse cardiovascular events was not decreased in patients with ulcerative colitis may be explained by the fact that systemic inflammation is more common in Crohn’s disease than in ulcerative colitis, the authors noted.

Hospitalizations for inflammatory bowel disease were somewhat more common in the anti-TNF group for both Crohn’s disease (OR 1.13, 95% CI 1.04-1.23) and ulcerative colitis (OR 1.53, 95% CI 1.29-1.81).

The observation that lower mortality rates seen in this analysis appeared to relate to cardiovascular disease and hip fracture as well as to the presence of serious or multiple comorbidities may have implications for treatment, the team said. Such a patient population, “which is rarely included in clinical trials and for whom some physicians may be reluctant to treat with chronic immunosuppression, may be particularly good candidates for anti-TNF agents such as corticosteroid-sparing therapy.”

Limitations of the study, the researchers said, included its residual confounding and reliance on administrative data.

The study was funded by the Patient Centered Outcomes Research Institute (PCORI).

The authors reported financial relationships with Celgene, Shire, Janssen, AbbVie, Immune Pharmaceuticals, AstraZeneca, Amgen, MedImmune, Merck, Nestle Health Science, Takeda, Pfizer, Ili Lilly, Gilead, Samsung Bioepis, Johnson & Johnson, Lycera, Evidera, GlaxoSmithKline, Janssen, Bristol-Myers Squibb, UCB, and Crescendo.

2018-01-24T14:00:00-0500

Tagged with:

About author

Related Articles